Phoenix Financial Ltd. Increases Stake in AbbVie Inc. $ABBV

Phoenix Financial Ltd. increased its stake in AbbVie Inc. (NYSE:ABBV) by 11.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 30,805 shares of the company’s stock after purchasing an additional 3,069 shares during the quarter. Phoenix Financial Ltd.’s holdings in AbbVie were worth $7,134,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of ABBV. Stonegate Investment Group LLC raised its stake in AbbVie by 0.6% during the 3rd quarter. Stonegate Investment Group LLC now owns 40,253 shares of the company’s stock worth $9,320,000 after acquiring an additional 222 shares during the period. CCG Wealth Management LLC increased its stake in shares of AbbVie by 5.1% in the third quarter. CCG Wealth Management LLC now owns 1,902 shares of the company’s stock worth $440,000 after purchasing an additional 92 shares in the last quarter. CFM Wealth Partners LLC increased its stake in shares of AbbVie by 6.1% in the third quarter. CFM Wealth Partners LLC now owns 24,408 shares of the company’s stock worth $5,651,000 after purchasing an additional 1,394 shares in the last quarter. Clarendon Private LLC raised its position in shares of AbbVie by 9.7% during the 3rd quarter. Clarendon Private LLC now owns 5,043 shares of the company’s stock valued at $1,168,000 after purchasing an additional 446 shares during the period. Finally, Paragon Private Wealth Management LLC lifted its stake in shares of AbbVie by 1.1% during the 3rd quarter. Paragon Private Wealth Management LLC now owns 12,002 shares of the company’s stock valued at $2,779,000 after buying an additional 130 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $220.55 on Tuesday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market capitalization of $389.80 billion, a P/E ratio of 167.09, a P/E/G ratio of 0.90 and a beta of 0.36. The stock has a 50 day moving average price of $225.33 and a 200 day moving average price of $217.78.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the previous year, the business earned $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a report on Tuesday, November 4th. Morgan Stanley boosted their price target on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Citigroup lowered their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. Finally, Scotiabank started coverage on shares of AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $248.11.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.